Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1‐year naturalistic study of schizophrenia patients in Japan

Ye, Wenyu; Fujikoshi, Shinji; Nakahara, Naohiro; Takahashi, Mariko; Ascher-Svanum, Haya; Ohmori, Tetsuro

doi:10.1111/j.1440-1819.2012.02351.x

Cited by 6 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 55 Fourteen studies in our review reported on the duration of the illness. 20 , 21 , 23 , 24 , 30 , 34 , 36 , 37 , 42 , 44 , 46 , 52 , 56 , 61 A comparison of the employment rates and the duration of the disorder between these studies did not show a consistent pattern of declining rates with longer duration of the disorder. For example, McCreadie 44 reported an employment rate of 8% in study participants, with an average duration of 8 years, while Middelboe et al 46 reported an employment rate of 12% in participants, with an average duration of 15 years.…”

Section: Resultsmentioning

confidence: 84%

See 1 more Smart Citation

Employment and the associated impact on quality of life in people diagnosed with schizophrenia

Bouwmans¹,

Sonneville²,

Mulder

et al. 2015

NDT

View full text Add to dashboard Cite

A systematic review was conducted to assess the employment rate of people with schizophrenia. Additionally, information from the selected studies concerning factors associated with employment and health-related quality of life (HRQoL) was examined. Employment rates ranged from 4% to 50.4%. The studies differed considerably in design, patient settings, and methods of recruitment. The most frequently reported factors associated with employment were negative and cognitive symptoms, age of onset, and duration and course of the disease. Individual characteristics associated with unemployment were older age, lower education, and sex (female). Additionally, environmental factors, eg, the availability of welfare benefits and vocational support programs, seemed to play a role. Generally, being employed was positively associated with HRQoL. However, the causal direction of this association remained unclear, as studies on the bidirectional relationship between employment and HRQoL were lacking.

show abstract

Section: Resultsmentioning

confidence: 84%

“…No study was found exclusively focusing on inpatients. Only in the study of Ye et al 61 were figures of employment rates for in-and outpatients separately presented. Both the baseline and follow-up employment rates in persons treated as outpatients were almost four times higher in comparison with the rates among inpatients.…”

Section: Resultsmentioning

confidence: 99%

Employment and the associated impact on quality of life in people diagnosed with schizophrenia

Bouwmans¹,

Sonneville²,

Mulder

et al. 2015

NDT

View full text Add to dashboard Cite

show abstract

“…A study by Roussidis and colleagues showed that switching a patient’s antipsychotic medication for reasons related to lack of efficacy and/or tolerability was associated with a significantly improved clinical benefit and increased adherence to treatment [ 74 ]. Similarly, studies of patients switching to olanzapine [ 28 ], quetiapine [ 29 , 34 ], ziprasidone [ 33 , 75 ], aripiprazole [ 76 ], long-acting injectable risperidone [ 32 , 77 ], or paliperidone [ 36 ] have reported improvements in cognitive function, psychotic symptoms, and/or tolerability during up to one year of treatment. However, the current analysis is the only switch study to examine long-term changes in subjective responses, tolerability, adherence-related attitude, and HRQoL using the disease-specific PETiT assessment.…”

Section: Discussionmentioning

confidence: 99%

Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia

et al. 2016

View full text Add to dashboard Cite

BackgroundLong-term improvement of health-related quality of life (HRQoL) in schizophrenia may improve adherence and reduce relapse and rehospitalization. This analysis examines long-term changes in HRQoL among patients with schizophrenia switched to lurasidone from other antipsychotics.MethodsPatients who completed an open-label 6-week switch study continued on lurasidone for an additional 24-weeks. HRQoL was measured using the self-reported Personal Evaluation of Transitions in Treatment (PETiT) scale and Short-Form 12 (SF-12) questionnaire. The PETiT assessed HRQoL via total and domain scores (adherence-related attitude and psychosocial functioning). The SF-12 assessed patients’ mental and physical component summary scores (MCS and PCS). Mean changes from the initial baseline were calculated at extension baseline and extension endpoint using analysis of covariance models. Analyses were further stratified by prior antipsychotic medication and responder status; responders were defined as having a ≥20 % improvement in Positive and Negative Syndrome Scale during the first 6-weeks of treatment.ResultsThe analysis included 144 patients with PETIT or SF-12 data who received ≥1 dose of lurasidone. Mean (standard deviation) PETiT total score improved significantly from 34.9 (9.3) at baseline to 39.5 (8.9) at extension baseline and 39.1 (9.0) at extension endpoint, representing improvements of 4.5 (7.9) and 5.1 (7.2) points, respectively (both p < 0.001). Significant improvements in adherence-related attitude and psychosocial functioning were observed at extension baseline and extension endpoint (all p < 0.001). Improvement in SF-12 MCS score was observed at extension baseline and endpoint, and PCS score at extension endpoint (all p < 0.01). Patients who switched from quetiapine and aripiprazole showed significant improvement of PETiT total score and adherence-related attitude at extension baseline and extension endpoint. In addition, patients who switched from quetiapine, risperidone, aripiprazole, or ziprasidone showed significant improvement in MCS scores from baseline to extension endpoint. Responders to lurasidone demonstrated greater improvement in PETiT total, psychosocial functioning, and MCS scores at extension baseline than nonresponders.ConclusionsAfter switching to lurasidone, patients with schizophrenia experienced HRQoL improvements that were sustained for an additional 24 weeks of treatment. Further study is warranted to understand the implications of these improvements in terms of employment, adherence, relapse, and rehospitalization.Trial registrationClinical trials.gov identifier NCT01143090 (June 10th, 2010).

show abstract

“…[10] In a 1 year naturalistic study, a significant number of patients who switched from risperidone to olanzapine experienced significant improvement in clinical and functional outcomes. [11] A Cochrane review concluded that olanzapine improved the general mental state (total positive and negative syndrome scale [PANSS] score) better than risperidone. [12]…”

Section: Introductionmentioning

confidence: 99%

Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia

Kumar

Anish

Rajmohan

2016

Indian J Psychiatry

View full text Add to dashboard Cite

Objective:The safety and efficacy profile of risperidone and olanzapine were compared in a double-blind trial that used doses widely accepted in clinical practice.Methods:Subjects (n = 71) who met Diagnostic and Statistical Manual of Mental Disorders-IV criteria for schizophrenia were randomly assigned to receive 2–8 mg/day of risperidone (mean modal dose = 5.5 mg/day) or 5–20 mg/day of olanzapine (mean modal dose = 14.4 mg/day) for 1 year.Results:The two study groups were similar at baseline in all aspects. Seventy-four percent of the participants completed the trial, with no between-differences in the proportion of dropouts. Olanzapine group showed significantly greater improvement in negative symptoms in assessments at 3rd, 6th, 9th, and 12th months (P = 0.05, 0.00, 0.00, and 0.00, respectively). Clinical global impression of severity (CGI-S) scores were consistently lower in the olanzapine group at 3rd, 6th, and 9th months (P = 0.01, 0.03, and 0.05, respectively) as measured by positive and negative symptom scale (PANSS). Total scores on PANSS, positive symptoms, general psychopathology, and CGI improvement showed comparable improvement at 3rd, 6th, 9th, and 12th months of follow-up (all subjects, including dropouts). Severity of extrapyramidal symptoms was low in both groups, with no between-group differences. Mean change in body weight, fasting blood sugar, and fasting cholesterol was comparable in both groups. Risperidone group had significant hyperprolactinemia after one year (P = 0.03).Conclusions:Both treatments were well-tolerated and efficacious. Greater reductions in severity of the illness and negative symptoms were seen with olanzapine consistently through 1 year. The frequency and severity of extrapyramidal symptoms were negligible and similar in the two treatment groups. Weight gain, hyperlipidemia, and hyperglycemia were comparable in both groups. Risperidone produced significant hyperprolactinemia.

show abstract

Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1‐year naturalistic study of schizophrenia patients in Japan

Cited by 6 publications

References 28 publications

Employment and the associated impact on quality of life in people diagnosed with schizophrenia

Employment and the associated impact on quality of life in people diagnosed with schizophrenia

Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia

Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia

Contact Info

Product

Resources

About